CKDXY - Opthea initiates OPT-302 Diabetic Macular Edema clinical trial January, 03 2018 07:30 AM Opthea Ltd ADR Opthea Limited (OTCPK:CKDXY) has commenced a Phase 1b/2a trial evaluating the safety and efficacy of OPT-302 in patients with center-involved diabetic macular edema (DME). More news on: Opthea Limited ADR, Healthcare stocks news, Read more ...